Anthony R Mato

List of Publications by Year
in descending order

101 papers	7,051 citations	126907 33 h-index	60623 81 g-index
102 all docs	102 docs citations	102 times ranked	7585 citing authors

#	Article	IF	Citations
1	Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. New England Journal of Medicine, 2017, 377, 2545-2554.	27.0	1,390
2	Ibrutinibâ€“Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2019, 381, 432-443.	27.0	545
3	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood, 2014, 124, 2354-2361.	1.4	382
4	Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncology, The, 2016, 17, 200-211.	10.7	373
5	Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica, 2018, 103, 874-879.	3.5	329
6	Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2018, 19, 65-75.	10.7	314
7	Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncology, The, 2016, 17, 1409-1418.	10.7	290
8	Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Journal of Clinical Oncology, 2021, 39, 3441-3452.	1.6	266
9	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet, The, 2021, 397, 892-901.	13.7	260
10	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood, 2020, 136, 1134-1143.	1.4	248
11	Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood, 2016, 128, 2199-2205.	1.4	166
12	The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clinical Cancer Research, 2016, 22, 2684-2696.	7.0	157
13	Frontâ€line, doseâ€escalated immunochemotherapy is associated with a significant progressionâ€free survival advantage in patients with doubleâ€hit lymphomas: a systematic review and metaâ€analysis. British Journal of Haematology, 2015, 170, 504-514.	2.5	140
14	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica, 2018, 103, 1511-1517.	3.5	135
15	Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. Journal of Clinical Oncology, 2017, 35, 2260-2267.	1.6	132
16	Long-term outcomes for ibrutinibâ€“rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood, 2022, 140, 112-120.	1.4	93
17	Mechanisms of Resistance to Noncovalent Brutonâ€™s Tyrosine Kinase Inhibitors. New England Journal of Medicine, 2022, 386, 735-743.	27.0	87
18	Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia, 2020, 34, 3047-3049.	7.2	81

#	Article	IF	Citations
19	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. Clinical Cancer Research, 2020, 26, 3589-3596.	7.0	80
20	Mutations in the RNA Splicing Factor SF3B1 Promote Tumorigenesis through MYC Stabilization. Cancer Discovery, 2020, 10, 806-821.	9.4	73
21	Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate. Blood, 2018, 132, 298-298.	1.4	73
22	Gray zone lymphoma with features intermediate between classical <scp>H</scp>odgkin lymphoma and diffuse large <scp>B</scp>â€cell lymphoma: <scp>C</scp>haracteristics, outcomes, and prognostication among a large multicenter cohort. American Journal of Hematology, 2015, 90, 778-783.	4.1	71
23	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Clinical Cancer Research, 2019, 25, 4264-4270.	7.0	61
24	Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis. Cancer Discovery, 2019, 9, 1452-1467.	9.4	60
25	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Advances, 2020, 4, 3977-3989.	5.2	55
26	Outcomes of frontâ€line ibrutinib treated CLL patients excluded from landmark clinical trial. American Journal of Hematology, 2018, 93, 1394-1401.	4.1	52
27	Comparable outcomes in chronic lymphocytic leukaemia (<scp>CLL</scp>) patients treated with reducedâ€dose ibrutinib: results from a multiâ€centre study. British Journal of Haematology, 2018, 181, 259-261.	2.5	51
28	The Graft-Versus-Myeloma Effect: Chronic Graft-Versus-Host Disease but Not Acute Graft-Versus-Host Disease Prolongs Survival in Patients with Multiple Myeloma Receiving Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1211-1216.	2.0	47
29	Postâ€treatment (not interim) positron emission tomographyâ€computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with Râ€HyperCVAD. Cancer, 2012, 118, 3565-3570.	4.1	42
30	Realâ€world clinical experience in the Connect^{Â®} chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. British Journal of Haematology, 2016, 175, 892-903.	2.5	42
31	Biosimilars in Oncology in the United States. JAMA Oncology, 2018, 4, 241.	7.1	41
32	Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3KÎ´ inhibitor therapy. Blood, 2021, 137, 2817-2826.	1.4	38
33	A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs. Blood, 2015, 126, 478-485.	1.4	37
34	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocyticÂleukaemia treated with ibrutinib from 3 clinical trials. British Journal of Haematology, 2018, 182, 504-512.	2.5	37
35	BTK Inhibitors in Cancer Patients with COVID-19: â€œThe Winner Will be the One Who Controls That Chaosâ€•(Napoleon Bonaparte). Clinical Cancer Research, 2020, 26, 3514-3516.	7.0	36
36	Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATEâ„¢-17 Trial. Blood, 2014, 124, 327-327.	1.4	33

#	Article	IF	Citations
37	NCCN GuidelinesÂ® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 622-634.	4.9	33
38	Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia. Cancer Biology and Therapy, 2018, 19, 1-2.	3.4	32
39	Overcoming resistance to targeted therapies in chronic lymphocytic leukemia. Blood Advances, 2021, 5, 334-343.	5.2	32
40	Elevation in serum lactate at the time of Febrile Neutropenia (FN) in hemodynamically-stable patients with Hematologic Malignancies (HM) is associated with the development of septic shock within 48 hours. Cancer Biology and Therapy, 2010, 9, 585-589.	3.4	28
41	Autologous stem cell transplantation in first complete remission may not extend progressionâ€free survival in patients with peripheral T cell lymphomas. American Journal of Hematology, 2016, 91, 672-676.	4.1	27
42	Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. Haematologica, 2019, 104, 2258-2264.	3.5	26
43	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. Blood Advances, 2019, 3, 1568-1573.	5.2	26
44	First-In-Human Study Of AMG 319, a Highly Selective, Small Molecule Inhibitor Of PI3KÎ´, In Adult Patients With Relapsed Or Refractory Lymphoid Malignancies. Blood, 2013, 122, 678-678.	1.4	26
45	Novel strategies for relapsed and refractory acute myeloid leukemia. Current Opinion in Hematology, 2008, 15, 108-114.	2.5	24
46	Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 114-124.e2.	0.4	23
47	Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor. Blood, 2019, 134, 501-501.	1.4	23
48	Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia. JAMA Network Open, 2019, 2, e1916326.	5.9	22
49	Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 174-183.e3.	0.4	21
50	Management of <scp>CLL</scp> patients early in the <scp>COVID</scp>â€19 pandemic: An international survey of <scp>CLL</scp> experts. American Journal of Hematology, 2020, 95, E199-E203.	4.1	20
51	The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. British Journal of Haematology, 2020, 188, 918-923.	2.5	19
52	Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)?. Blood, 2019, 133, 121-129.	1.4	18
53	How We Manage Patients With Chronic Lymphocytic Leukemia During the SARSâ€CoVâ€2ÂPandemic. HemaSphere, 2020, 4, e432.	2.7	18
54	Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 438-444.e1.	0.4	18

#	Article	IF	Citations
55	Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS. International Journal of Hematologic Oncology, 2017, 6, 113-121.	1.6	15
56	Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients. Blood, 2019, 134, 4311-4311.	1.4	15
57	Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2013, 54, 2606-2612.	1.3	14
58	Utility of the systemic inflammatory response syndrome (SIRS) criteria in predicting the onset of septic shock in hospitalized patients with hematologic malignancies. Cancer Biology and Therapy, 2009, 8, 1095-1100.	3.4	13
59	Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies. Cancer Biology and Therapy, 2018, 19, 636-643.	3.4	13
60	Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 580-591.	3.8	13
61	Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States. Leukemia and Lymphoma, 2019, 60, 955-963.	1.3	12
62	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a realâ€world setting. A GIMEMAâ€ERIC and US study. Cancer Medicine, 2020, 9, 8468-8479.	2.8	12
63	The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. Blood Advances, 2020, 4, 1407-1418.	5.2	12
64	The potential of pirtobrutinib in multiple B-cell malignancies. Therapeutic Advances in Hematology, 2022, 13, 204062072211016.	2.5	12
65	Utilizing Real-World Evidence (RWE) to Improve Care in Chronic Lymphocytic Leukemia: Challenges and Opportunities. Current Hematologic Malignancy Reports, 2020, 15, 254-260.	2.3	11
66	Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have Undergone Prior Allogeneic Stem Cell Transplant. Blood, 2014, 124, 4697-4697.	1.4	11
67	The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: <i>post-hoc</i> analyses from the phase III MURANO study. Haematologica, 2022, 107, 134-142.	3.5	11
68	Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: â€œWhat's Past Is Prologueâ€• (Shakespeare). Clinical Cancer Research, 2022, 28, 603-608.	7.0	11
69	PET/Computed Tomography in Chronic Lymphocytic Leukemia and Richter Transformation. PET Clinics, 2019, 14, 405-410.	3.0	10
70	Evidence for and Against Green Tea and Turmeric in the Management of Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e421-e426.	0.4	9
71	A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib. Haematologica, 2022, 107, 2630-2640.	3.5	9
72	Approaches for relapsed CLL after chemotherapy-free frontline regimens. Hematology American Society of Hematology Education Program, 2020, 2020, 10-17.	2.5	8

#	Article	IF	Citations
73	Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. Haematologica, 2020, 106, 284-287.	3.5	8
74	Evidence-Based Minireview: Treatment of relapsed chronic lymphocytic leukemia after venetoclax. Hematology American Society of Hematology Education Program, 2020, 2020, 18-23.	2.5	8
75	Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Brutonâ€™s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia. Drug Design, Development and Therapy, 2021, Volume 15, 919-926.	4.3	7
76	Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. Leukemia and Lymphoma, 2021, 62, 1940-1948.	1.3	7
77	Serum Lactic Acid (LA) as a Predictor of Septic Shock in Patients with Hematologic Malignancies (HM) Who Develop Febrile Neutropenia. Blood, 2008, 112, 666-666.	1.4	7
78	Emerging Strategies in Treating Double Hit Lymphomas. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 563-568.	0.4	6
79	Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy. Drugs, 2022, 82, 133-143.	10.9	6
80	A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3KÎ´ inhibitor therapy.. Journal of Clinical Oncology, 2018, 36, 7530-7530.	1.6	5
81	Real-World Prognostic Biomarker Testing, Treatment Patterns and Dosing Among 1461 Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the informCLL Prospective Observational Registry. Blood, 2020, 136, 42-43.	1.4	5
82	Real-World Evidence for Chronic Lymphocytic Leukemia in the Era of Targeted Therapies. Cancer Journal (Sudbury, Mass), 2019, 25, 442-448.	2.0	4
83	Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies. Blood, 2019, 134, 502-502.	1.4	4
84	COVID-19 Impact on Lymphoma Patients' Clinical Outcomes - an Observational Cohort Study. Blood, 2020, 136, 6-7.	1.4	4
85	Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2022, 174, 103696.	4.4	4
86	Searching for a home: phosphoinositide 3â€kinase inhibitors for chronic lymphocytic leukaemia in modern clinical practice. British Journal of Haematology, 2021, 194, 9-10.	2.5	3
87	A Phase II Study of the Combination of FCR-Lite and Lenalidomide Followed By Lenalidomide Maintenance in Front-Line CLL: The FCR2 Regimen. Blood, 2014, 124, 4678-4678.	1.4	2
88	The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy . Blood and Lymphatic Cancer: Targets and Therapy, 2020, Volume 10, 1-5.	2.7	1
89	All in the family: back-to-back kinase inhibitors for the treatment of chronic lymphocytic Leukemia. Haematologica, 2021, 106, 2300-2301.	3.5	1
90	Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Brutonâ€™s Tyrosine Kinase Inhibitors. Hematology/Oncology Clinics of North America, 2021, 35, 793-806.	2.2	1

#	Article	IF	Citations
91	Comparison of Contrast-Enhanced CT, PET/CT, PET, and Low-Dose Non-Contrast Enhanced CT Imaging of Diffuse Large B-Cell, Follicular, Small Lymphocytic/CLL, and Marginal Zone Lymphomas.. Blood, 2009, 114, 1402-1402.	1.4	1
92	Front-Line, Dose-Escalated Immunochemotherapy Is Associated with a Significant PFS (but not OS) Advantage in 401 Patients (Pts) with Double-Hit Lymphomas (DHL): A Systematic Review and Meta-Analysis. Blood, 2014, 124, 3056-3056.	1.4	1
93	Systemic Inflammatory Response Syndrome (SIRS) as Predictor of Severe Sepsis (SS) in Hospitalized Patients (pts) with Hematologic Malignancies.. Blood, 2007, 110, 633-633.	1.4	1
94	Novel-agent combination therapies in chronic lymphocytic leukemia: the law of relative Contributions. Haematologica, 2022, , .	3.5	1
95	Liquid Tumors in the Elderly. Clinics in Geriatric Medicine, 2012, 28, 115-152.	2.6	0
96	A Predictive Model for Cytogenetic Risk Group in Elderly AML: The Penn Cytogenetic Surrogate Score (PCSS).. Blood, 2006, 108, 4446-4446.	1.4	0
97	A Prospective Clinical Trial of a Novel Epstein-Barr Virus (EBV) PCR Panel in Patients with EBV Associated Malignancies.. Blood, 2007, 110, 2628-2628.	1.4	0
98	The Impact of Autoimmune Disease on Clinical Outcomes of Patients with DLBCL and FL. Blood, 2014, 124, 2974-2974.	1.4	0
99	Patterns of Care of Aged Chronic Lymphocytic Leukemia Patients in the United States: Systematic Analysis of 457 Patients in the Connect CLL Registry. Blood, 2014, 124, 4672-4672.	1.4	0
100	Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE). Blood, 2020, 136, 19-22.	1.4	0
101	Optimizing Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 581-583.	4.9	0